NASDAQ$ZVRA
Zevra Therapeutics Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full-year ended December 31, 2019.
KemPharm reported Q4 2019 revenue of $1.4 million from research and development services, and a net loss of $6.0 million, or $0.18 per share. The company's cash and investments totaled $3.6 million as of December 31, 2019. They anticipate KP415 NDA submission in Q1 2020.
- KP415 NDA remains on track for Q1 2020 submission.
- Q4 2019 revenue was $1.4 million from research and development services.
- Q4 2019 net loss was $6.0 million, or $0.18 per share.
- Cash and investments totaled $3.6 million as of December 31, 2019.
Headline financials
Revenue & EPS history
Zevra · Revenue · Quarterly
$1.38M
Forward guidance
KemPharm expects research and development services revenue to continue through FY 2020 and beyond as they provide consultation services to support their partner in their commercial preparation activities for KP415 and with the potential initiation of the product development plan for KP484.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
-0.2%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+3.8%
Avg return
30 days after
45%
20 / 44 earnings
Positive
+35.2%
Q2 2015
Best reaction
-19.4%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.0% | +1.6% | -0.1% | |
| Q4 2025 | +21.3% | +9.4% | +6.5% | |
| Q3 2025 | -9.8% | -6.4% | -13.5% | |
| Q1 2025 | +3.0% | +2.7% | +8.3% | |
| Q4 2024 | -2.1% | -2.1% | +10.5% | |
| Q3 2024 | -3.5% | -3.8% | -5.8% | |
| Q2 2024 | +2.6% | +8.2% | +11.5% | |
| Q1 2024 | -2.7% | -5.5% | -10.1% | |
| Q4 2023 | -13.3% | -13.9% | -23.9% | |
| Q3 2023 | -3.5% | -9.0% | +12.7% | |
| Q2 2023 | +3.8% | -4.2% | -2.7% | |
| Q1 2023 | +3.1% | +27.7% | +37.1% | |
| Q4 2022 | -19.4% | -22.8% | +4.9% | |
| Q3 2022 | -18.3% | -17.6% | -19.7% | |
| Q2 2022 | -5.4% | -14.6% | -4.3% | |
| Q1 2022 | +2.0% | +15.9% | +9.5% | |
| Q4 2021 | -4.7% | -1.3% | -15.3% | |
| Q3 2021 | -0.1% | -2.1% | -9.9% | |
| Q2 2021 | -9.4% | -7.2% | -7.6% | |
| Q1 2021 | +3.4% | +10.8% | +65.9% | |
| Q4 2020 | +19.5% | +14.4% | -8.3% | |
| Q3 2020 | -5.2% | +6.2% | +83.0% | |
| Q2 2020 | +8.7% | +46.8% | +48.9% | |
| Q1 2020 | -13.5% | -21.2% | -27.3% | |
| Q4 2019 | -0.9% | -8.5% | -30.9% | |
| Q3 2019 | +11.3% | -5.5% | -21.6% | |
| Q2 2019 | -15.8% | -18.3% | -25.8% | |
| Q1 2019 | +4.9% | +9.0% | +17.2% | |
| Q4 2018 | -14.6% | -16.2% | -32.4% | |
| Q3 2018 | -1.9% | -6.9% | +8.4% | |
| Q2 2018 | +5.5% | +0.0% | +13.7% | |
| Q1 2018 | +16.8% | +23.8% | +35.6% | |
| Q4 2017 | -9.9% | -13.2% | -29.1% | |
| Q3 2017 | +1.4% | +0.0% | +1.4% | |
| Q2 2017 | +8.5% | -8.5% | +9.3% | |
| Q1 2017 | +0.0% | +3.8% | +2.5% | |
| Q4 2016 | +9.7% | +18.1% | +31.9% | |
| Q3 2016 | +3.8% | +3.8% | -3.8% | |
| Q2 2016 | +0.0% | +7.7% | +22.0% | |
| Q1 2016 | -15.7% | — | — | |
| Q4 2015 | +0.7% | — | — | |
| Q3 2015 | -8.8% | — | — | |
| Q2 2015 | +35.2% | — | — | |
| Q1 2015 | -2.7% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro